Litigation Resource Community

Title	Views
1	Introducing LexisNexis Author Steve Posner’s Blog On Privacy, Surveillance Issues	7373
2	Mealey's Litigation Report: Discovery	6183
3	Welcome To Our New Communities!	5897

Title

Views

Introducing LexisNexis Author Steve Posner’s Blog On Privacy, Surveillance Issues

7373

Mealey's Litigation Report: Discovery

6183

Welcome To Our New Communities!

5897

Title	Downl.
1	Mealey's Litigation Report: Discovery	43
2	Mealey’s Litigation Report: Class Actions	8
3	5th New York Courts Newsletter Covers Hot Topics, Trends	8

Title

Downl.

Mealey's Litigation Report: Discovery

Mealey’s Litigation Report: Class Actions

5th New York Courts Newsletter Covers Hot Topics, Trends

2nd Circuit Affirms Injunction Against Lawyer Who Disclosed Zyprexa MDL Documents

NEW YORK - (Mealey's) The Zyprexa multidistrict litigation court properly enjoined an Alaska attorney and mental health advocate from obtaining and disseminating confidential discovery documents produced by Eli Lilly and Co., a panel of the Second...

Published Thu, Aug 12 2010 2:40 PM by Tom Moylan

Filed under: lawsuit, litigation, torts, MDL, Lanier Law Firm, Mealey's, personal injury, multidistrict litigation, Eli Lilly, Zyprexa, injunction, Second Circuit, James B. Gottstein, drugs and devices, David Egilman
AstraZeneca Settles Nearly 4,000 Seroquel Injury Claims; Terms Confidential

LONDON - (Mealey's) AstraZeneca PLC said July 29 that it has agreed in principle to settle with nearly 4,000 Seroquel product liability plaintiffs. The company said settlement terms are confidential. In notes to its second-quarter financial report...

Published Fri, Jul 30 2010 10:40 AM by Tom Moylan

Filed under: litigation, Seroquel, torts, personal injury, multidistrict litigation, Janssen, drugs, product liability, Eli Lilly, settle, AstraZeneca, Bristol-Myers Squibb
2nd Circuit Reject Overpromotion Exception To Learned Intermediary In Zyprexa Case

NEW YORK - (Mealey's) A Second Circuit U.S. Court of Appeals panel on July 16 ruled that a Zyprexa multidistrict litigation plaintiff failed to show that alleged overpromotion of the atypical antipsychotic drug by manufacturer Eli Lilly and Co. misled...

Published Fri, Jul 16 2010 4:52 PM by Tom Moylan

Filed under: lawsuit, litigation, torts, personal injury, diabetes drugs, Dwight L. Dean v. Eli Lilly and Co., antipsychotic drugs, Dr. Roger Rousseau, Eli Lilly, Zyprexa, Dwight L. Dean

Litigation Resource Community

Featured Content

You are not logged in. Please Login to add content to your community page

Visit Other Communities By

Latest Postings

Most Viewed Postings

Popular Downloads

2nd Circuit Affirms Injunction Against Lawyer Who Disclosed Zyprexa MDL Documents

AstraZeneca Settles Nearly 4,000 Seroquel Injury Claims; Terms Confidential

2nd Circuit Reject Overpromotion Exception To Learned Intermediary In Zyprexa Case